Elicio Therapeutics Inc ELTX

$1.90 -0.04 (-2.06%)

Valuation

Market cap
51,473,000
Revenue TTM
$0
Net income TTM
$-39,570,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
1.20

Trading

Volume
464,000
Avg volume
324,024
Day's range
$1.79 – $1.98
Shares out
27,091,000
Stochastic %K
85%
Beta
1.32
Analysts
Strong Sell
Price target
$14.38

Price

Company profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide trea...

Show more

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 209 0050
Website
https://elicio.com
Address
451 D Street, 5th Floor Suite 501, Boston, United States

Latest news

Stocktwits

grncandle Oct 25, 6:57 PM
$PACB & $ELTX Golden/17
0 replies
humdime Oct 25, 2:43 PM
$ELTX Finally, daraxonrasib!
0 replies
nhyujm6 Oct 23, 7:56 PM
$ELTX Strange to think the result here would have been very different if it wasn't for about 20 patients. Sell and ask questions later - a few days ago I was buying as many shares I wanted at 1.49 - there is enough interest in KRAS, vaccines and the broad applicability of this platform for ELTX to build back from here in my opinion.
0 replies
Merlintrader Oct 23, 1:29 PM
Latest company news, Oct 23: the ESMO abstract for $ELTX's AMPLIFY-7P confirms the miss on the primary disease-free survival endpoint (HR 0.85, p=0.539). It adds subgroup and post-hoc analyses, and the 99% immunogenicity figure refers to evaluable patients rather than clinical response. The oral presentation is today in Madrid. How the data, the Q1 2027 runway and the Nov 12 annual meeting fit together: ELTX Stock: Elicio News, AMPLIFY-7P & Funding https://www.merlintrader.com/elicio-therapeutics-stock-hub/
0 replies
OpenOutcrier Oct 23, 1:01 PM
$ELTX (-11.9% pre) Elicio phase 2 pancreatic cancer trial misses primary endpoint https://ooc.bz/l/118363
1 replies
humdime Oct 23, 7:33 AM
$ELTX https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products? The FDA recommends adjusting for covariates. This post-hoc analysis could perfectly well have been agreed upon in advance as a prespecified analysis. HR=0,45
0 replies
topstockalerts Oct 23, 12:02 AM
$ELTX the market seems to like this one
0 replies
humdime Oct 22, 10:42 PM
$ELTX Tomorrows presentation looks very interesting. The ctDNA imbalance between the two arms may have significantly impacted the primary results, with the adjusted Cox model showing an HR of 0.45. Some of the other subgroup findings are also very interesting. I think these data are encouraging for a potential P3 trial, although Im not sure how the market will react.
0 replies